Dataset Information

Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis.

ABSTRACT: Patients with multidrug-resistant tuberculosis in Peru and South Africa were randomized to a weight-banded nominal dose of 11, 14, 17, or 20 mg/kg/day levofloxacin (minimum, 750 mg) in combination with other second-line agents. A total of 101 patients were included in noncompartmental pharmacokinetic analyses. Respective median areas under the concentration-time curve from 0 to 24 h (AUC0-24) were 109.49, 97.86, 145.33, and 207.04 ?g · h/ml. Median maximum plasma concentration (Cmax) were 11.90, 12.02, 14.86, and 19.17 ?g/ml, respectively. Higher levofloxacin doses, up to 1,500 mg daily, resulted in higher exposures. (This study has been registered at ClinicalTrials.gov under identifier NCT01918397.).

SUBMITTER: Peloquin CA

PROVIDER: S-EPMC6153781 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis.

Peloquin Charles A CA Phillips Patrick P J PPJ Mitnick Carole D CD Eisenach Kathleen K Patientia Ramonde F RF Lecca Leonid L Gotuzzo Eduardo E Gandhi Neel R NR Butler Donna D Diacon Andreas H AH Martel Bruno B Santillan Juan J Hunt Kathleen Robergeau KR Vargas Dante D von Groote-Bidlingmaier Florian F Seas Carlos C Dianis Nancy N Moreno-Martinez Antonio A Kaur Pawandeep P Horsburgh C Robert CR

Antimicrobial agents and chemotherapy 20180924 10

Patients with multidrug-resistant tuberculosis in Peru and South Africa were randomized to a weight-banded nominal dose of 11, 14, 17, or 20 mg/kg/day levofloxacin (minimum, 750 mg) in combination with other second-line agents. A total of 101 patients were included in noncompartmental pharmacokinetic analyses. Respective median areas under the concentration-time curve from 0 to 24 h (AUC<sub>0-24</sub>) were 109.49, 97.86, 145.33, and 207.04 μg · h/ml. Median maximum plasma concentration (<i>C</ ...[more]

PMID: 30012767

Dataset Information

Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis.

Publications

Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Similar Datasets

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis.
| S-EPMC6005123 | biostudies-literature

Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients.
| S-EPMC5527618 | biostudies-literature

Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children.
| S-EPMC4888594 | biostudies-literature

Discovery and characterization of the tuberculosis drug lead ecumicin.
| S-EPMC5450905 | biostudies-literature

Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa.
| S-EPMC2958014 | biostudies-literature

Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures.
| S-EPMC5806153 | biostudies-literature

Treatment of Drug-Resistant Tuberculosis.
| S-EPMC7000172 | biostudies-literature

Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis.
| S-EPMC5527578 | biostudies-literature

Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions.
| S-EPMC7160048 | biostudies-literature

Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.
| S-EPMC6260169 | biostudies-literature